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Abstract: Malaria, known as the “fevers,” has been treated for over three thousand years in 
China with extracts of plants of the genus Artemisia (including Artemisia annua, A. opiacea, 
and A. lancea) from which the active compound is artemisin, a sesquiterpene that is highly 
effective in the treatment of the disease, especially against young forms of the parasite. South 
American Indians in the seventeenth century already used an extract of the bark of chinchona 
tree, commonly named “Jesuits’ powder.” Its active compound was isolated in 1820 and its 
use spread all over the world being used as a prophylactic drug during the construction of the 
Madeira–Mamoré railroad in the beginning of the twentieth century. During the 1920s to the 
1940s, new antimalarial drugs were synthesized to increase the arsenal against this parasite. 
However, the parasite has presented systematic resistence to conventional antimalarial drugs, 
driving researchers to ﬁ  nd new strategies to treat the disease. In the present review we discuss 
how Brazil treats Plasmodium-infected patients.
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Introduction
Malaria is one of the worst health problems in this decade according to the World 
Health Organization (WHO). Globally, the disease takes the heavy toll of more than 
one million lives every year. Most of the victims are under the age of ﬁ  ve. These 
astonishing numbers show that one infant dies of malaria every 30 seconds. In the face 
of this dramatic situation, malaria still continues to receive insufﬁ  cient attention, due 
to the fact that the disease mainly affects tropical and subtropical regions of the world 
rather than temperate zones where industrial and ﬁ  nancial power are concentrated. 
For this reason, malaria is considered a neglected disease.
Considering the pharmaceutical treatment of malaria, we encounter several dif-
ﬁ  culties. Since the ﬁ  rst antimalarial drug synthesis, advances in the comprehension 
of its mode of action and in the development of new effective antimalarials have been 
disappointing. The need for low-cost drugs, problems of drug toxicity, and the spread 
of antimalairal drug resistance in the parasite combine to create a very disturbing 
scenario for malaria management.
Improving malaria treatment is, more than ever, an issue of great importance. 
Despite increasing investments in measures against the disease, this problem still 
needs highly skilled approaches to provide effective prevention and treatment of the 
disease.1
Antimalarials
The ﬁ  rst historical record of a compound with antimalarial properties dates back 
to 1638, when the physician Juan de la Vega administered quina, the bark of a tree 
native to tropical South America now known as cinchona, to the wife of the Viceroy 
of Peru, treating her illness effectively.2 In 1820 quinine was discovered to be the 
active compound of quina’s antimalarial properties. For a long time, quinine was the 
only antimalarial drug available, and its economic importance rose substantially in Therapeutics and Clinical Risk Management 2009:5 312
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the 19th century. Many attempts to synthesize the compound 
were unsuccessful, until an efﬁ  cient synthesis method was 
described in 1944. Although quinine has been widely used 
for centuries, it has high toxicity and needs to be administered 
several times a day due to its short pharmacological half-life.3 
Hence, efforts were mobilized to ﬁ  nd suitable substitutes 
for quinine. In 1891, Guttman and Ehrlich were the ﬁ  rst to 
report the antimalarial properties of a synthetic compound 
when they observed the successful treatment of two patients, 
using the dye methylene blue.4
Much later, in 1932, the synthesis of the ﬁ  rst antimalarial, 
pamaquine, was achieved,5 followed by the synthesis of 
atebrin (quinacrine), an 8-aminoquinoline derivative, with 
antimalarial properties.6
However, due to the high toxicity of these 8-aminoquinolines, 
new efforts were made in 1940s to ﬁ  nd alternatives, leading 
to the discovery and synthesis of new antimalarials. The 
new drugs included proguanil, the ﬁ  rst antifolate used to 
treat malaria, and the two 4-aminoquinolines resochin (later 
renamed chloroquine) and sontaquine, as well as quinine, as 
already mentioned.7 Chloroquine rapidly gained popularity 
due to its high efﬁ  ciency, low toxicity, cheap production cost 
and high availability.8 Unfortunately, improper usage in a 
single-drug regimen during the 1950s and 1960s led to the 
emergence of chloroquine-resistant parasites.9
During the last few decades, only a small number of 
new antimalarials have been made available as suitable 
drugs to treat and control malaria effectively, although 
during the period 1975–1999 almost 1400 new drugs were 
registered worldwide.10 This new generation included the 
4-quinoline-methanol, meﬂ  oquine,11 the 9-phenanthrene-
methanol, halofantrine,12 the 8-aminoquinoline, primaquine, 
the 2-hydroxinaphthoquinone, atovaquone (discovered in the 
early 1940s, but only licensed in 1997),13 the artemisin-based 
compounds such as artesunate and the antifolates such as 
sulfadoxine and pyrimethamine.
Most of the antimalarials available nowadays fall into 
three classes: the quinolines, the artemesin-based antimalari-
als, and the antifolates. However, drug resistance to these 
compounds is spreading rapidly and we face a situation 
where, in some cases, almost no completely effective drug 
can be found to treat malaria.14
The discovery and development of new effective anti-
malarial drugs are now issues of great importance. Rather 
than focusing investment in the traditional mass-screening 
of chemicals for antimalarial action, the aim needs to turn 
to increase the understanding of how available antimalarials 
Table 1 Classiﬁ  cation of blood schizonticidal drugs and their mechanism of action
Group Drug Metabolic target
4-Aminoquinolines Chloroquine 
Amodiaquine
Hemoglobin digestion by the parasite
Methanolquinolines Quinine 
Meﬂ  oquine 
Halofantrine
Hemoglobin digestion by the parasite
Artemisinin family Artemesinin (qinghaosu) Protein metabolism
Artemisinin family Artesunate Protein metabolism




Lincosamide antibiotic Clindamycine 
Lincomycine
Protein synthesis protein synthesis
Table 2 First choice scheme, recommended in the three day 
treatment of Plasmodium falciparum infections with artemether + 
lumefantrine (Coartem®)
Weight Age Dosage for three days
5–14 kg 6 months to 2 years 1 tablet 12/12 hours
15–24 kg 3 to 8 years 2 tablets 12/12 hours
25–34 kg 9 to 14 years 3 tablets 12/12 hours
35 kg 14 years 4 tablets 12/12 hours
Notes: Each Coartem® blister has an individual dosage for the treatment of one 
person. Coartem® comes in four types of packaging, to match patient weight and age. 
On the ﬁ  rst day, the second dose can be administered at intervals of 8 to 12 hours.
Table 3 Second choice scheme, recommended in the three day 
treatment of Plasmodium falciparum infections
Drug Dosage
Artesunate 600 mg plus
Meﬂ  oquine 250 mg
1 tablet daily for 3 days
6 tablets 1 unique dose (1,5 g)Therapeutics and Clinical Risk Management 2009:5 313
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work at the molecular level in order to provide a sound 
rationale for the design of new and better drugs.
Antimalarial action
For the most exploited group of antimalarials, the quinolines, 
little is known about how precisely they work, although 
there are many hypotheses. The ﬁ  rst fact that needs to be 
highlighted is that some quinolines, particularly chloro-
quine, tend to accumulate in the parasite’s digestive vacuole 
(food vacuole), suggesting that this acidic compartment 
might be their main site of action. An interesting model has 
been proposed to explain this unusual accumulation, based 
on the known behavior of such weak diprotic bases. It is 
possible that, after entering the parasite, these quinolines 
become trapped inside the digestive vacuole where in its 
acid environment they gain an extra proton to add to their 
original monoprotonated state. With this additional proton, 
the quinolines are unable to pass back through the enclosing 
membrane of the digestive vacuole.
The observed accumulation of quinolines in the diges-
tive vacuole prompted further work on their mode of action, 
which led to the discovery of another very peculiar effect, 
their inhibition of the synthesis of the hemozoin pigment by 
the parasite.15 This pigment is formed in the digestive vacuole 
as a result of the parasite’s feeding on the hemoglobin within 
the red blood cell it inhabits.
The digestion of hemoglobin is catalyzed in the digestive 
vacuole by several proteolytic enzymes including plasmep-
sins I, II, and IV, histoaspartic protease (HAP), falcipain 2, 
falcipain 3, and falcilysin.15 Beside the aminoacids generated 
from the degradation of the protein component of hemoglo-
bin, toxic intermediates derived from the heme group are 
also produced, but these are rapidly converted by the parasite 
into the nontoxic crystalline brown pigment, hemozoin. This 
detoxiﬁ  cation process entails ﬁ  rst the oxidation of the heme 
product ferrous protoporphyrin IX, into ferric protoporphyrin 
IX, also called hematin.
Ferric protoporphyrin IX then aggregates by a nonen-
zymatic process into crystals of hemozoin. The process 
of crystallization is not fully understood and may require 
parasite-derived molecules to initiate. It is hypothetized 
that quinolines inhibit this process, causing a toxic accu-
mulation which is fatal to the parasite. However, some 
data suggest that a strong inhibition of hemozoin synthesis 
is not necessarily correlated with a higher antimalarial 
activity, which weakens the hemozoin inhibition hypoth-
esis. Another interesting effect caused by quinolines, in 
particular by chloroquine, is the mobilization of Ca2+ from 
compartments within the parasite.16,17 Since this second 
messenger is exploited by the parasite to modulate its own 
life cycle and several other cellular functions,18–21 it would 
not be surprising that a disruption in Plasmodium Ca2+ 
Table 4 Recommended scheme for the treatment of Plasmodium falciparum infections with quinine for three days plus doxicyclin for 
ﬁ  ve days and primaquine on the sixth day









8 to 11 years 1 and ½ tablet 1 tablet 1 tablet 1 tablet
12 to 14 years 2½ tablets 1½ tablet 1½ tablet 2 tablets
15 years or more 4 tablets 2 tablets 2 tablets 3 tablets
Notes: Quinine and doxicycline should be administered twice a day, each 12 hours, doxiciclyne and primaquine should not be administered to pregnant women, and primaquine 
is administered in order to eliminate P. falciparum gametocytes.
Table 5 Recommended scheme for the treatment of Plasmodium falciparum infections with quinine for three days plus clindamycin for 
ﬁ  ve days, in pregnant women or children less than eight years old or contraindication to the use of tetracyclin
Drugs and dosage age 1st, 2nd, and 3rd day 4th and 5th day
 Quinine Clindamycin Clindamycin
8 years 30 mg/kg/day each 8 hours 20 mg/kg/day each 12 hours 20 mg/kg/day each 12 hours
8 to 11 years 1½ tablets 20 mg/kg/day each 12 hours 20 mg/kg/day each 12 hours
12 to 14 years 2½ tablets 20 mg/kg/day each 12 hours 20 mg/kg/day each 12 hours
15 years or more 4 tablets 20 mg/kg/day each 12 hours 20 mg/kg/day each 12 hours
Note: The dosage of quinine must be given each 12 hours (each tablet is 500 mg).Therapeutics and Clinical Risk Management 2009:5 314
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homeostasis leads eventually to parasite death. Several 
studies on Plasmodium Ca2+ signaling and homeostasis 
have been published,18–27 showing the crucial role of this 
ion in the parasite life cycle.
The remaining class of antimalarials, the artemisin-
related compounds, are thought to act by cleaving peroxide 
bridges, thus generating toxic free radicals. This cleaving 
could be related to the high efﬁ  ciency of artemisinin action, 
and the food vacuole is a possible target.28
In the past twenty years, the Brazilian Ministry of Health, 
together with the Fundação Nacional da Saúde (National 
Health Foundation) aided by a committee of specialists, has 
periodically updated malaria therapeutics in the country, 
taking into consideration personal experiences or experi-
ences based on evidence that is more suitable to Brazilian 
reality.29,30 Generally speaking, the traditional antimalarial 
chemical entities remain as the main drugs (Table 1) with 
the association of two drugs, generally differing in their 
capacity/speed of cleaning of blood-stage parasites in order 
to avoid the appearing of drug-resistant falciparum malaria. 
The classical association of chloroquine and primaquine was 
maintained for malaria vivax treatment, with some alterations 
or recommendations regarding the dosage.29,30
In 2007 and 2008, the Ministry of Health introduced new 
associations: artemisine and lumefantrine (Coartem®) (Table 2) 
and artesunate with meﬂ  oquine (Artequin®) (Table 3).
Table 6 Recommended scheme for severe malaria due to P. falciparum
Drugs Important observations
 1.  First choice
A. Artemesinin derivates
Intravenous artesunate: 2.4 mg/kg as “attack dose” 
and 1.2 mg/kg after 4, 24, and 48 hours. Each dose should be 
diluted in 500 mL of isotonic solution (preferably 5% or 10% 
glucose), infused in one hour.
B. Intramuscular  artemether
Injected at 4 mg/kg one dose in the ﬁ  rst day.   After 24 hours, 
inject 2 mg/kg each 24 hours for 
4 days in one dose for a total of 5 days of treatment.
The treatment should be complemented with clindamycin, 20 mg/kg each 
12 hours for 5 days; or with doxicycline 3.3 mg/kg divided in two doses 
each 12 hours for 5 days; or meﬂ  oquine 15–20 mg/kg in one unique dose. 
These drugs should be administered at the end of the treatment with 
artemisinin derivates. Doxacycline should not be administered to pregnant 
women and children less than eight years old. Meﬂ  oquine should not be 
administered to women in the ﬁ  rst trimester of pregnancy.
 2.  Second choice
A. Intravenous  quinine  (quinine  dichloride)
Infusion of 20–30 mg/kg/day, diluted in isotonic solution (preferably 
5% or 10% glucose, maximum of 500 ml) for 4 hours of continuous 
IV infusion, divided in three doses a day (8/8 hours).
B.  Intravenous quinine associated with intravenous clindamycin 
Quinine dosage should be used as described above for 3 days. 
Concomitantly, clindamycin, 20 mg/kg should be administered in 
two doses each 12 hours, diluted in a 5% or 10% glucose infusion 
solution (15 ml/kg), dripping slowly, in one hour for 7 days.
When the patient is able to swallow and the parasite load is declining, oral 
quinine sulfate should be used, with the same dosage, each 8 hours. The 
treatment should be maintained until 48 hours after a negative result of 
the thick smear (generally 7 days)
Scheme indicated to pregnant women
Notes: Artemisin derivates have proven to be very effective and rapidly reduce or eliminate parasites. Therefore, it is necessary that these medications are protected from 
their abusive use and indicated only for serious and complicated cases. The preferential speciﬁ  c therapeutic scheme for pregnant women is the association of quinine and 
intravenous clindamycin due to its effectiveness and because it causes no harm either to the mother or to the child.
Table 7 Alternative scheme for the treatment of Plasmodium falciparum infections in children, with artesunate suppository capsules in 
four days, with the administration of one dose of meﬂ  oquine in the third day














1 to 2 years 1 1 ½ 1 ½
3 to 5 years 2 (A) 2 (A) 1 1 1
6 to 9 years 3 (B) 3 (B) 1½ 1 1½
10 to 12 years 3 (B) 3 (B) 2½ 3 (B) 2
Abbreviations: A, Administration of one suppository capsule each 12 hours; B, Administration of one suppository capsule each 8 hours.
Notes: Suppository capsules may be stored at room temperature; Meﬂ  oquine may be administered in a 15–20 mg/kg dose, twice a day, each 12 hours. This scheme is not 
applicable in diarrheic children.Therapeutics and Clinical Risk Management 2009:5 315
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According to handbooks, therapeutic schemes may be 
divided according to parasite specimen and case serious-
ness with special attention to special categories such as 
children or special situations such as allergies, intolerance, 
or contraindication.29,30 For small children, smash the tablet 
to make the administration easier, and have them swallow 
it with water or milk. It is recommended that children take 
the tablet with food. Do not administer the drug to pregnant 
women in their ﬁ  rst trimester of pregnancy nor to children 
less then six months of age.
P. falciparum malaria
Among the four forms of malaria, the disease caused by 
P. falciparum brings is the one that brings more concern 
to physicians, due to its high pathogenicity and resistance 
to drugs.9,10–14 Nowadays, in the Amazonian rural areas, the 
combination of quinine and antibiotics is still widely used 
(Table 4), although the tertiary and secondary centers of 
reference (large hospitals in specialized centers), gener-
ally choose to use Coartem®. However, in areas outside the 
Amazonian region, the use of the classical association quinine 
and tetracycline derivates is preconized, especially doxicy-
cline and the use of clindamycin (when there is restriction 
to the use of doxicycline) (Table 5). We should emphasize 
that the use of artemisinin derivates of parenteral formula-
tion is restricted to the serious malaria cases according to 
the Ministry of Health guidelines29,30 (Table 6), and that 
alternative rectal administration is also of value when the use 
of oral treatment or parenteral administration is impossible 
(Table 7). Although the use of meﬂ  oquin in the treatment of 
P. falciparum malaria does not present signs of signiﬁ  cant 
resistance in Brazil,31 its use in monotherapy or associated 
to primaquine has been prohibited in the endemic areas by 
the present committee.
It is worth remembering that the association with only 
one dose of primaquine should be present when using 
quinine monotherapy or in combination to destroy the sexual 
forms.
As presented above, the character of malaria treatment 
in Brazil varies, according to the studied area. In some areas 
the use of quinine in monotherapy in pregnant women is still 
used in a seven day scheme (Table 8).
P. vivax malaria
Vivax malaria, less virulent than P. falciparum malaria, 
is the most common form of the disease in Brazil.29,30 
Although the classical association of chloroquine with 
primaquine (Table 9) for vivax malaria treatment has not 
changed in the past 20 years, chloroquine infusions were 
abolished due to operational problems. Therefore, in some 
cases intravenous medications for P. falciparum malaria are 
applied to treat vivax malaria. Nowadays, there is a tendency 
Table 8 Quinine 7-day monotherapy in children
Drugs and dosage age Quinine 500 mg tablet 
(Daily dose for 7 days)
Less than 6 months ¼
6 to 11 months ½
1 to 2 years ¾
3 to 6 years 1
7 to 11 years 1½
12 to 14 years 2
14 years 3
Table 9 Scheme recommended for Plasmodium vivax infections with chloroquine (3 days) and primaquine (7 days)
Drugs and 
dosage age












Adult Child Adult Child Adult Child
Less than 6 months ¼ – – ¼ – – – –
6 to 11 months ½ – 1 ½ – 1 – 1
1 to 2 years 1 – 1 ½ – 1 – 1
3 to 6 years 1 – 2 1 – 2 – 2
7 to 11 years 2 1 1 1½ 1 1 1 1
12 to 14 years 3 1½ – 2 1½ – 1½ –
15 years 4 2–3 2–2–
Notes: Primaquine: Adult 15 mg tablets and child 5 mg tablets. Chloroquine and primaquine should be taken with small meals, preferably. Do not administer primaquine to 
pregnant women and children less than six months of age.Therapeutics and Clinical Risk Management 2009:5 316
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to maintain 1.5 g of chloroquine and adequate primaquine 
doses for patients weighing more than 70 kg. In case of 
malaria recurrence, a 50% to 100% increase in the initial 
dose of primaquine is recommended. In cases in which 
primaquine cannot be used (pregnant women, children less 
than six months old, persons who are deﬁ  cient in glucose 
6-phosphate dehydrogenase enzyme, allergic persons, etc.), 
exclusive chloroquine therapy may be given29,30 as mentioned 
in Table 10.
Malaria caused by other 
plasmodium species
Treatment of malaria caused by P. ovale is performed with 
the same protocols used for vivax malaria. Malaria caused by 
P. malariae, although the less frequently diagnosed in Brazil, 
should be treated as malaria P. vivax (Table 10), except for 
the use of primaquine, since this parasite does not present 
hypnozoitic forms.
Conclusion
Malaria parasites have a complex life cycle. The struggle 
against the disease – not only in Brazil but in the whole 
world – is now facing a huge obstacle: the increasing 
appearance of parasites resistant to the classical antimalarials. 
Funding incentives in the area of neglected diseases have 
been the focus of Brazilian funding agencies, thus supporting 
work on several aspects such as epidemiology, system 
biology, immunology, and others. The multidisciplinary work 
is a necessity to help us to understand better this pathogen’s 
tricks and to achieve new forms, tools, and strategies to 
continue the battle against this disease.
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